Oleolive awarded NIH funding to study oleocanthal and alzheimer’s

Oleolive is incredibly excited to announce our award by the NIH (National Institutes of Health) and NIA (National Institue on Aging) to further our efforts in studying oleocanthal for the treatment/prevention of Alzheimer's and related dementias. 

Oleolive's goal is to make oleocanthal available to anyone that wants to use it and validate its efficacy through rigorous, peer-reviewed science. We are creating a brand that can be trusted to have solid principles behind its claims and recycling resources to combat diseases that currently have no preventative or treatment. 

Our team has worked tirelessly to move this mission forward and this is a huge step in the right direction for us. 

Congratulations to the Oleolive team and we are looking forward to the future!

------------------------------

Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number R43AG061952. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Previous
Previous

Oleolive Inc was awarded funding from the National Heart, Lung, and Blood Institute to study a repurposed drug to treat lung fibrosis.